What is Celularity Inc's earnings per share (EPS)?

Celularity Inc (CELU) reported diluted earnings per share of $-3.59 for fiscal year 2025. This represents a -36.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Celularity Inc Financials

CELU

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Celularity Inc (CELU) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CELU FY2024 2026-04-22

A sharp operating reset lifted gross economics and cut burn, but liquidity still trails the income-statement improvement.

In FY2024, gross margin more than doubled to 72.4% while operating cash burn narrowed to -$6.4M, which points to a real shift in cost mix and spending discipline rather than a sales rebound alone. But with just $738K of cash and a 0.4x current ratio, the business is still being run with very little working-capital slack.

The company’s earnings quality looks better than it did in FY2022, when net income was positive even as operating cash flow was -$137.9M; by FY2024, that operating cash deficit had narrowed to -$6.4M. That makes the reported loss more representative of actual cash use, not just an accounting swing.

Balance-sheet pressure remains the operating backdrop: liabilities reached $123.8M against only $8.8M of equity, so the recent burn reduction did not translate into much financial cushion. In practice, that means execution now matters alongside access to outside capital.

Financial Health Signals

Financial Profile 8/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Celularity Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Celularity Inc has an operating margin of -230.9%, meaning the company retains $-231 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -70.8% the prior year.

Growth

Celularity Inc's revenue declined 51% year-over-year, from $54.2M to $26.6M. This contraction results in a growth score of 47/100.

Leverage

Celularity Inc has elevated debt relative to equity (D/E of -0.89), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

Celularity Inc's current ratio of 0.15 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

While Celularity Inc generated -$13.3M in operating cash flow, capex of $161K consumed most of it, leaving -$13.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Weak

1/9

Celularity Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

0.14x

For every $1 of reported earnings, Celularity Inc generates $0.14 in operating cash flow (-$13.3M OCF vs -$91.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-89.5x

Celularity Inc earns $-89.5 in operating income for every $1 of interest expense (-$61.3M vs $685K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$26.6M

YoY-51.0%

5Y CAGR+13.2%

Celularity Inc generated $26.6M in revenue in fiscal year 2025. This represents a decrease of 51.0% from the prior year.

EBITDA

-$54.0M

YoY-77.5%

Celularity Inc's EBITDA was -$54.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 77.5% from the prior year.

Net Income

-$91.7M

YoY-58.4%

Celularity Inc reported -$91.7M in net income in fiscal year 2025. This represents a decrease of 58.4% from the prior year.

EPS (Diluted)

$-3.59

YoY-36.0%

Celularity Inc earned $-3.59 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 36.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$13.4M

YoY-104.4%

Celularity Inc generated -$13.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 104.4% from the prior year.

Cash & Debt

$6.2M

YoY+736.7%

5Y CAGR-35.3%

Celularity Inc held $6.2M in cash against $33.8M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

29M

YoY+28.3%

Celularity Inc had 29M shares outstanding in fiscal year 2025. This represents an increase of 28.3% from the prior year.

Margins & Returns

Gross Margin

24.4%

YoY-48.0pp

5Y CAGR-41.1pp

Celularity Inc's gross margin was 24.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 48.0 percentage points from the prior year.

Operating Margin

-230.9%

YoY-160.2pp

5Y CAGR+833.1pp

Celularity Inc's operating margin was -230.9% in fiscal year 2025, reflecting core business profitability. This is down 160.2 percentage points from the prior year.

Net Margin

-345.4%

YoY-238.7pp

5Y CAGR+1113.0pp

Celularity Inc's net profit margin was -345.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 238.7 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$15.0M

YoY-13.6%

5Y CAGR-22.2%

Celularity Inc invested $15.0M in research and development in fiscal year 2025. This represents a decrease of 13.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$161K

YoY+0.0%

5Y CAGR-64.3%

Celularity Inc invested $161K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 0.0% from the prior year.

CELU Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$26.6M-51.0%	$54.2M+138.1%	$22.8M+26.7%	$18.0M-15.7%	$21.3M+49.4%	$14.3M
Cost of Revenue	$20.1M+33.9%	$15.0M-6.4%	$16.0M	N/A	N/A	N/A
Gross Profit	$6.5M-83.5%	$39.2M+480.8%	$6.8M+499.7%	-$1.7M-114.5%	$11.7M+25.0%	$9.3M
R&D Expenses	$15.0M-13.6%	$17.4M-42.9%	$30.5M-61.1%	$78.4M-11.3%	$88.4M+67.6%	$52.7M
SG&A Expenses	$51.3M-12.6%	$58.6M+16.0%	$50.6M-23.4%	$66.0M-7.5%	$71.3M+127.7%	$31.3M
Operating Income	-$61.3M-59.8%	-$38.4M+80.1%	-$192.3M-651.1%	-$25.6M+76.5%	-$109.1M+28.2%	-$151.9M
Interest Expense	$685K	N/A	N/A	N/A	N/A	N/A
Income Tax	$3K	N/A	$10K-23.1%	$13K-35.0%	$20K+100.4%	-$4.7M
Net Income	-$91.7M-58.4%	-$57.9M+70.5%	-$196.3M-1483.1%	$14.2M+114.2%	-$100.1M+51.9%	-$208.2M
EPS (Diluted)	$-3.59-36.0%	$-2.64	$-11.02	$0.95	$-1.49	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$4.1M-22.3%	$5.3M-7.9%	$5.7M-49.8%	$11.4M-37.0%	$18.1M+95.1%	$9.3M-23.2%	$12.1M-17.5%	$14.7M
Cost of Revenue	$7.4M+88.9%	$3.9M-25.5%	$5.2M+47.5%	$3.6M-51.6%	$7.3M+89.1%	$3.9M+82.9%	$2.1M+29.5%	$1.6M
Gross Profit	-$3.3M-337.0%	$1.4M+179.4%	$494K-93.7%	$7.9M-27.0%	$10.8M+99.3%	$5.4M-45.8%	$10.0M-23.4%	$13.0M
R&D Expenses	$3.3M-27.2%	$4.6M+37.2%	$3.4M-10.1%	$3.7M-2.6%	$3.8M-2.2%	$3.9M+3.0%	$3.8M-35.0%	$5.8M
SG&A Expenses	$15.1M+61.9%	$9.3M-26.3%	$12.6M-11.4%	$14.3M-11.2%	$16.1M+26.9%	$12.7M-20.5%	$15.9M+13.4%	$14.0M
Operating Income	-$22.1M-71.0%	-$12.9M+18.7%	-$15.9M-51.3%	-$10.5M-13.0%	-$9.3M+19.5%	-$11.5M-13.3%	-$10.2M-37.9%	-$7.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Net Income	-$24.4M-5.6%	-$23.1M+5.9%	-$24.5M-24.1%	-$19.8M-48.6%	-$13.3M+17.4%	-$16.1M-148.1%	-$6.5M+70.5%	-$22.0M
EPS (Diluted)	N/A	$-0.88+13.7%	$-1.02-21.4%	$-0.84	N/A	$-0.73-143.3%	$-0.30+70.9%	$-1.03

CELU Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$107.3M-19.1%	$132.7M-7.8%	$143.9M-64.1%	$401.1M-3.2%	$414.1M-3.9%	$431.0M
Current Assets	$12.3M-40.1%	$20.6M+3.9%	$19.8M-40.9%	$33.5M-43.3%	$59.1M-18.1%	$72.2M
Cash & Equivalents	$6.2M+736.7%	$738K+225.1%	$227K-98.4%	$14.0M-62.5%	$37.2M-31.4%	$54.3M
Inventory	$571K-89.4%	$5.4M-6.0%	$5.8M+8.4%	$5.3M-44.4%	$9.5M0.0%	$9.5M
Accounts Receivable	$116	N/A	N/A	N/A	N/A	N/A
Goodwill	$7.3M0.0%	$7.3M0.0%	$7.3M-93.9%	$119.7M-2.9%	$123.3M0.0%	$123.3M
Total Liabilities	$145.4M+17.4%	$123.8M+20.3%	$102.9M-49.1%	$202.2M-35.8%	$314.7M-67.3%	$962.4M
Current Liabilities	$80.8M+50.4%	$53.7M-20.2%	$67.3M+8.4%	$62.1M+136.8%	$26.2M-1.7%	$26.7M
Long-Term Debt	$33.8M	N/A	N/A	N/A	N/A	N/A
Total Equity	-$38.1M-530.7%	$8.8M-78.4%	$41.0M-79.4%	$198.9M+100.1%	$99.4M+118.7%	-$531.4M
Retained Earnings	-$991.5M-10.2%	-$899.7M-6.9%	-$841.8M-30.4%	-$645.5M+2.7%	-$663.7M-17.8%	-$563.6M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$107.3M-6.0%	$114.2M-5.0%	$120.3M-6.7%	$128.9M-2.9%	$132.7M+3.0%	$128.8M-4.9%	$135.5M-5.8%	$143.8M
Current Assets	$12.3M+16.3%	$10.6M-38.6%	$17.3M-21.8%	$22.1M+7.4%	$20.6M+41.8%	$14.5M-18.2%	$17.7M-22.4%	$22.9M
Cash & Equivalents	$6.2M+5045.8%	$120K-86.1%	$863K+194.5%	$293K-60.3%	$738K+454.9%	$133K-71.5%	$467K-75.4%	$1.9M
Inventory	$571K-77.7%	$2.6M-41.9%	$4.4M-28.8%	$6.2M+14.6%	$5.4M+36.5%	$4.0M+36.0%	$2.9M-21.2%	$3.7M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$7.3M0.0%	$7.3M0.0%	$7.3M0.0%	$7.3M0.0%	$7.3M0.0%	$7.3M0.0%	$7.3M0.0%	$7.3M
Total Liabilities	$145.4M+8.2%	$134.3M-7.9%	$145.8M+8.5%	$134.4M+8.5%	$123.8M+11.0%	$111.6M+3.6%	$107.7M-4.3%	$112.6M
Current Liabilities	$80.8M+23.6%	$65.3M-5.7%	$69.2M+18.0%	$58.7M+9.3%	$53.7M-29.5%	$76.2M+12.2%	$67.9M+2.8%	$66.0M
Long-Term Debt	$33.8M-5.2%	$35.7M	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$38.1M-89.4%	-$20.1M+21.2%	-$25.5M-363.1%	-$5.5M-162.3%	$8.8M-48.9%	$17.3M-37.9%	$27.8M-11.0%	$31.2M
Retained Earnings	-$991.5M-2.5%	-$967.1M-2.4%	-$944.0M-2.7%	-$919.5M-2.2%	-$899.7M-1.5%	-$886.4M-1.8%	-$870.3M-0.8%	-$863.8M

CELU Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$13.3M-107.1%	-$6.4M+83.5%	-$38.7M+71.9%	-$137.9M-25.2%	-$110.1M-74.2%	-$63.2M
Capital Expenditures	$161K0.0%	$161K-84.6%	$1.0M-80.0%	$5.2M-15.6%	$6.2M-77.7%	$27.8M
Free Cash Flow	-$13.4M-104.4%	-$6.6M+83.5%	-$39.7M+72.2%	-$143.1M-23.1%	-$116.3M-27.8%	-$91.0M
Investing Cash Flow	$514K0.0%	$514K+112.7%	-$4.0M+22.7%	-$5.2M+11.3%	-$5.9M+53.9%	-$12.8M
Financing Cash Flow	$18.6M+178.3%	$6.7M-72.2%	$24.1M-79.9%	$119.8M+21.6%	$98.6M-3.4%	$102.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$256K

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$5.1M-22.7%	-$4.2M-316.3%	-$999K+66.6%	-$3.0M-287.8%	$1.6M+1206.9%	-$144K+95.8%	-$3.4M+21.7%	-$4.4M
Capital Expenditures	N/A	N/A	N/A	N/A	$91K	$0-100.0%	$31K-20.5%	$39K
Free Cash Flow	N/A	N/A	N/A	N/A	$1.5M+1143.8%	-$144K+95.9%	-$3.5M+21.7%	-$4.4M
Investing Cash Flow	N/A	N/A	N/A	N/A	-$1.6M	$0-100.0%	$2.1M+5597.4%	-$39K
Financing Cash Flow	$11.2M+222.6%	$3.5M+113.2%	$1.6M-29.7%	$2.3M+260.8%	$643K+913.9%	-$79K+12.2%	-$90K-101.4%	$6.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CELU Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	24.4%-48.0pp	72.4%+42.7pp	29.7%+39.1pp	-9.4%-64.2pp	54.8%-10.7pp	65.5%
Operating Margin	-230.9%-160.2pp	-70.8%+773.7pp	-844.4%-702.0pp	-142.4%+368.8pp	-511.2%+552.9pp	-1064.0%
Net Margin	-345.4%-238.7pp	-106.8%+755.3pp	-862.0%-941.0pp	79.0%+548.2pp	-469.3%+989.1pp	-1458.4%
Return on Equity	N/A	-655.1%-175.9pp	-479.2%-486.4pp	7.1%+107.8pp	-100.7%	N/A
Return on Assets	-85.5%-41.8pp	-43.6%+92.8pp	-136.4%-140.0pp	3.5%+27.7pp	-24.2%+24.1pp	-48.3%
Current Ratio	0.15-0.2	0.38+0.1	0.29-0.2	0.54-1.7	2.25-0.5	2.71
Debt-to-Equity	-0.89-14.9	14.01+11.5	2.51+1.5	1.02-2.1	3.17+5.0	-1.81
FCF Margin	-101.8%-89.7pp	-12.1%+162.4pp	-174.5%+621.7pp	-796.2%-251.1pp	-545.1%+92.4pp	-637.5%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	-79.7%-105.8pp	26.1%+17.5pp	8.6%-60.3pp	68.9%+9.4pp	59.5%+1.3pp	58.2%-24.2pp	82.5%-6.4pp	88.8%
Operating Margin	-537.5%-293.3pp	-244.1%+32.4pp	-276.6%-184.8pp	-91.8%-40.6pp	-51.2%+72.8pp	-124.0%-40.0pp	-84.0%-33.8pp	-50.2%
Net Margin	-593.6%-156.9pp	-436.7%-9.2pp	-427.6%-254.7pp	-172.9%-99.6pp	-73.3%+99.9pp	-173.2%-119.6pp	-53.6%+96.4pp	-149.9%
Return on Equity	N/A	N/A	N/A	N/A	-150.4%-57.3pp	-93.2%-69.8pp	-23.3%+47.1pp	-70.5%
Return on Assets	-22.7%-2.5pp	-20.2%+0.2pp	-20.4%-5.1pp	-15.3%-5.3pp	-10.0%+2.5pp	-12.5%-7.7pp	-4.8%+10.5pp	-15.3%
Current Ratio	0.150.0	0.16-0.1	0.25-0.1	0.380.0	0.38+0.2	0.19-0.1	0.26-0.1	0.35
Debt-to-Equity	-0.89+0.9	-1.78+3.9	-5.72+18.7	-24.41-38.4	14.01+7.6	6.46+2.6	3.87+0.3	3.60
FCF Margin	N/A	N/A	N/A	N/A	8.3%+9.8pp	-1.6%+27.2pp	-28.7%+1.5pp	-30.3%

Note: Shareholder equity is negative (-$38.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.15), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Mink Therapeutics, Inc. INKT

$54.2M

Abvc Biopharma Inc ABVC

$29.6M

Pmv Pharmaceuticals, Inc. PMVP

$67.2M

ARTIVA BIOTHERAPEUTICS INC ARTV

$382.4M

Applied Therapeutics APLT

$14.9M

Frequently Asked Questions

What is Celularity Inc's annual revenue?

Celularity Inc (CELU) reported $26.6M in total revenue for fiscal year 2025. This represents a -51.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Celularity Inc's revenue growing?

Celularity Inc (CELU) revenue declined by 51% year-over-year, from $54.2M to $26.6M in fiscal year 2025.

Is Celularity Inc profitable?

No, Celularity Inc (CELU) reported a net income of -$91.7M in fiscal year 2025, with a net profit margin of -345.4%.

What is Celularity Inc's EBITDA?

Celularity Inc (CELU) had EBITDA of -$54.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Celularity Inc have?

As of fiscal year 2025, Celularity Inc (CELU) had $6.2M in cash and equivalents against $33.8M in long-term debt.

What is Celularity Inc's gross margin?

Celularity Inc (CELU) had a gross margin of 24.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Celularity Inc's operating margin?

Celularity Inc (CELU) had an operating margin of -230.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Celularity Inc's net profit margin?

Celularity Inc (CELU) had a net profit margin of -345.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Celularity Inc's free cash flow?

Celularity Inc (CELU) generated -$13.4M in free cash flow during fiscal year 2025. This represents a -104.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Celularity Inc's operating cash flow?

Celularity Inc (CELU) generated -$13.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Celularity Inc's total assets?

Celularity Inc (CELU) had $107.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Celularity Inc's capital expenditures?

Celularity Inc (CELU) invested $161K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Celularity Inc spend on research and development?

Celularity Inc (CELU) invested $15.0M in research and development during fiscal year 2025.

How many shares does Celularity Inc have outstanding?

Celularity Inc (CELU) had 29M shares outstanding as of fiscal year 2025.

What is Celularity Inc's current ratio?

Celularity Inc (CELU) had a current ratio of 0.15 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Celularity Inc's debt-to-equity ratio?

Celularity Inc (CELU) had a debt-to-equity ratio of -0.89 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Celularity Inc's return on assets (ROA)?

Celularity Inc (CELU) had a return on assets of -85.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Celularity Inc's cash runway?

Based on fiscal year 2025 data, Celularity Inc (CELU) had $6.2M in cash against an annual operating cash burn of $13.3M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Celularity Inc's debt-to-equity ratio negative or unusual?

Celularity Inc (CELU) has negative shareholder equity of -$38.1M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Celularity Inc's Piotroski F-Score?

Celularity Inc (CELU) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Celularity Inc's earnings high quality?

Celularity Inc (CELU) has an earnings quality ratio of 0.14x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Celularity Inc cover its interest payments?

Celularity Inc (CELU) has an interest coverage ratio of -89.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Celularity Inc?

Celularity Inc (CELU) scores 8 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.